Listed by the USPTO as DONOGHUE, BRITTNEY ERIN
Tech Center 1600 • Art Units: 1644 1646 1649 1675
This examiner grants 59% of resolved cases
DONOGHUE, BRITTNEY ERIN is assigned to tech center 1600 and art unit 1644. The profile includes 104 resolved cases, a 58.7% allowance rate, and a median of 1318 days to allowance. The 47.4% interview lift is substantial relative to the allowance rate, making interview preparation a prominent consideration for applicants.
The leading companies are Regeneron Pharmaceuticals Inc., BEIJING HANMI PHARMACEUTICAL CO., LTD., and The Brigham and Women's Hospital Inc. The leading firms are Biospark Intellectual Property Law, CANTOR COLBURN LLP, and Ballard Spahr LLP. The limited case record supports a careful, application-specific reading of the measures.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18670375 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Final Rejection | Hoffmann-La Roche Inc. |
| 17785427 | BIFUNCTIONAL MOLECULES COMPRISING AN IL-7 VARIANT | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18769216 | Targeted IL-12 Treatments and Methods to Stimulate haNK and NK92mi Cells | Non-Final OA | NantBio, Inc. |
| 18274677 | Astrocyte Interleukin-3 Reprograms Microglia and Limits Alzheimer`s Disease | Non-Final OA | The General Hospital Corporation |
| 18612039 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18158767 | METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP | Final Rejection | SUN PHARMACEUTICAL INDUSTRIES LIMITED |
| 17778361 | NOVEL MULTISPECIFIC ANTIBODY FORMAT | Final Rejection | AMGEN INC. |
| 17600600 | COMBINATIONS OF TRANSCRIPTION INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF DISEASE | Non-Final OA | Board of Regents, The University of Texas System |
| 18466911 | PD-1 AGONIST ANTIBODIES | Non-Final OA | Otsuka Pharmaceutical Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy58.7% of resolved applications examined by Brittney Erin Donoghue were allowed (104 resolved cases), compared with 35.9% across Art Unit 1644 over the last five years.
This examiner's interview lift is +47.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Brittney Erin Donoghue took 1,318 days on average from filing to allowance.
Brittney Erin Donoghue examines applications in Art Unit 1644 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
